nach oben

Erschienen in:

03.10.2019 | Original Article

A phase I delayed-start, randomized and pharmacodynamic study of metformin and chemotherapy in patients with solid tumors

verfasst von: Mohammad Wasif Saif, Shrikar Rajagopal, Jennifer Caplain, Elizabeth Grimm, Oksana Serebrennikova, Madhumita Das, Philip N. Tsichlis, Robert Martell

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Metformin activates AMP-related pathways leading to inactivation of mammalian target of rapamycin (mTOR) and suppression of its downstream effectors, crucial for cancer growth. Epidemiologic studies showed a reduced incidence and improved survival in cancer patients. We conducted a prospective phase I study to assess the safety of metformin in combination with chemotherapy in patients with solid tumors.

Methods

We conducted a delayed-start randomized trial of non-diabetic patients in two stages. In Stage 1, we randomized patients to two arms: concurrent arm (metformin with chemo) vs. delayed arm (chemo alone). In Stage 2, patients in delayed arm were crossed over to receive metformin. Patients received metformin 500 mg twice daily with chemotherapy to define dose-limiting toxicities (DLTs) in both stages. Secondary endpoints assessed adverse events (AEs) and response rates. Translational correlates included effects of metformin on expression and phosphorylation of 5′ adenosine monophosphate-activated protein kinase (AMPK) by western blot in PBMCs.

Results

A total of 100 patients were enrolled (51 in delayed arm vs. 49 concurrent arm). Rate of DLTs in patients receiving metformin with chemotherapy was 6.1% vs. 7.8% in patients receiving chemotherapy alone. DLTs seen with addition of metformin included those associated with established chemo adverse events. No lactic acidosis or hypoglycemia occurred. Restaging showed stable disease in 46% at cessation of metformin. 28% of patients with measurable tumor markers showed improvement. AMPK phosphorylation showed a four- to sixfold increase in AMPK phosphorylation after metformin.

Conclusions

This is the largest phase I study of metformin combined with chemotherapy, which suggests that metformin can be given safely with chemotherapy, and offers a platform for future studies. Post-metformin increase in AMPK phosphorylation may potentially explain lack of disease progression in nearly half of our patients.

Funding

UL1 TR001064.

Clinical trial information

NCT01442870.

DeFronzo RA, Goodman AM (1995) Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333(9):541–549CrossRef

Soranna D, Scotti L, Zambon A et al (2012) Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes; a meta-analysis. Oncologist 17(6):813–822CrossRef

Jiralerspong S, Palla SL, Giordano SH et al (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27(20):3297–3302CrossRef

Zhang Y, Storr SJ, Johnson K et al (2014) Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basil-like breast cancer treated with radiotherapy. Oncotarget 5(24):12936–12949PubMedPubMedCentral

Spratt DE, Zhang C, Zumsteg ZS, Pei X, Zhang Z, Zelefsky MJ (2013) Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 63(4):709–716CrossRef

Higurashi T, Hosono K, Takahashi H et al (2016) Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicenter double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol 17(4):475–483CrossRef

Viollet B, Guigas B, Gardia NS, Leclerc J, Foretz M, Andreelli F (2012) Cellular and molecular mechanisms of metformin: an overview. Clin Sci 122(6):253–270CrossRef

Storozhuk Y, Hopmans SN, Sanli T et al (2013) Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer 108(10):2021–2032CrossRef

Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269–10273CrossRef

10.

Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167–1174CrossRef

11.

Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67:10804–10812CrossRef

12.

Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K (2009) Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69(19):7507–7511CrossRef

13.

Mehenni H, Gehrig C, Nezu J et al (1998) Loss of LKB1 kinase activity in Peutz–Jeghers syndrome, and evidence for allelic and locus heterogeneity. Am J Hum Genet 63:1641–1650CrossRef

14.

Machet G, Coudray JM (2000) Lactic acidosis and metformin implicated: why better information about risk factors? Therapie 55(2):283–294PubMed

15.

D’Agostino RB Sr (2009) The delayed-start study design. N Engl J Med 361:1304–1306CrossRef

16.

https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed 2 Oct 2019

17.

Ford TC, Rickwood D (1990) A new one-step method for the isolation of human mononuclear cells. J Immunol Methods 134:237–241CrossRef

18.

Lim CT, Lolli F, Thomas JD, Kola B, Korbonits M (2012) Measurement of AMP-activated protein kinase activity and expression in response to ghrelin. Methods Enzymol 514:271–287CrossRef

19.

Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN (2008) The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila Pa) 1:369–375CrossRef

20.

Schwartz LH, Litière S, de Vries E et al (2016) RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer 62:132–137CrossRef

21.

Home P, Kahn S, Jones N, Noronha D, Beck-Nielsen H, Viberti G (2010) Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 53(9):1838–1845CrossRef

22.

Lee AJ (1996) Metformin in noninsulin-dependent diabetes mellitus. Pharmacotherapy 16(3):327–351PubMed

23.

Joshua AM, Zannella VE, Downes MR et al (2014) A pilot ‘window of opportunity’ neoadjuvant study of metformin in localised prostate cancer. Prostate Cancer Prostatic Dis 17(3):252–258CrossRef

24.

Wang W, Guan KL (2009) AMP-activated protein kinase and cancer. Acta Physiol (Oxf) 196(1):55–63CrossRef

25.

Lee J, Hong EM, Kim JH, Jung JH, Park SW, Koh DH, Choi MH, Jang HJ, Kae SH (2019) Metformin induces apoptosis and inhibits proliferation through the AMP-activated protein kinase and insulin-like growth factor 1 receptor pathways in the bile duct cancer cells. J Cancer 10(7):1734–1744CrossRef

26.

Kalender A, Selvaraj A, Kim SY et al (2010) Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 11(5):390–401CrossRef

27.

Del Barco S, Vazquez-Martin A, Cufí S et al (2011) Metformin: multi-faceted protection against cancer. Oncotarget 2(12):896PubMedPubMedCentral

28.

Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K (2010) Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell 39:761–772CrossRef

29.

Iliopoulos D, Hirsch HA, Struhl K (2011) Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 71(9):3196–3201CrossRef

30.

Hanna RK, Zhou C, Malloy KM, Sun L, Zhong Y, Gehrig PA, Bae-Jump VL (2012) Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol Oncol 125(2):458–469CrossRef

Titel: A phase I delayed-start, randomized and pharmacodynamic study of metformin and chemotherapy in patients with solid tumors
verfasst von: Mohammad Wasif Saif
Shrikar Rajagopal
Jennifer Caplain
Elizabeth Grimm
Oksana Serebrennikova
Madhumita Das
Philip N. Tsichlis
Robert Martell
Publikationsdatum: 03.10.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 6/2019
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-019-03967-3

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

A phase I delayed-start, randomized and pharmacodynamic study of metformin and chemotherapy in patients with solid tumors